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Background: Hepatitis B virus (HBV) and hepatitis C virus (HBV) infections accounts for substantial proportions of the
world wide liver disease. The two hepatotropic virus share common modes of transmission and their co-infection are
common. Patients with dual HBV and HCV infection have more severe liver disease and are at increased risk of
progression to hepatic cell carcinoma. This study was aimed to assess the prevalence of HBV and HCV among patients
attending serology laboratory of Gondar University Teaching Hospital.
Methods: A retrospective study was conducted from January 2007 to December 2011 at serology laboratory of Gondar
University Teaching Hospital. Data were cross checked for completeness, entered and analyzed using SPSS version 16
statistical package.
Results: From the total of 2,684 clinicaly suspected hepatitis patients, 563 (20.98%) were positive for HBsAg and anti-HCV
test. Of all, 14.4% were seropositive for HBV (male= 7.89% female=6.27%) (p-value=0.011) while 12.4% were seropositive
for HCV (male =7.6% and female=4.13%) (p-value<0.001). The co-incidence of HBV and HCV were found to be 36 (6.39%)
(male=3.9% and female=2.4%) (p-value <0.001). Majority of HBV (30.2%) and HCV (30.7%) infections were detected among
age group of 25–34 years old (p-value=0.36) and 15–24 years old (p-value<0.001) respectively.
Conclusion: The overall prevalence of HBV and HCV is high. Males and younger age groups were more affected.
Community awareness about the transmission and prevention of viral hepatitis infection should be strengthened by
giving health education and herd immunization.
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Infection with hepatitis B virus (HBV) and hepatitis C
virus (HCV) affects the liver and results in a broad
spectrum of disease outcomes [1]. Hepatitis B virus is a
member of the family Hepadnaviridae which contain a
unique deoxyribonucleic acid (DNA) genome virus while
HCV is a member of family Flaviviridae under RNA
virus. An infection with HBV may spontaneously resolve
and lead to protective immunity, chronic infection and,
in rare cases, acute liver failure with a high risk of death.
In contrast to HBV, an infection with HCV becomes
chronic in most cases. People with chronic HBV and/or
HCV infection remain infectious to others and are at* Correspondence: Beletebiadigo@yahoo.com
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reproduction in any medium, provided the orrisk of serious liver disease such as liver cirrhosis or hep-
atic cell carcinoma (HCC) later in life [2,3].
Approximately one third of the world’s population has
been exposed to HBV and an estimated 350 million people
are chronically infected [3,4]. Nearly 350 million individ-
uals has been infected with HBV and each year, an esti-
mated 1 million persons die from chronic complications
of the disease. Although chronic HBV infection has a
worldwide distribution, the vast majority of infected per-
sons reside in Asia, the Middle East and Africa [5]. It has
been estimated that, annually, about 1.2 million people are
dying globally from chronic HBV infection, cirrhosis and
liver cancer [6].
The World Health Organization (WHO) estimated
that 3% of the world’s population are infected with HCV,
resulting in a total of 120 to 170 million people [7,8].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Socio-demographic characteristics of study
subjects at serology laboratory of Gondar University
teaching hospital from January 2007 to December 2011
Variables Frequency (n) Percentage (%)
Sex
Male 1311 48.8
Female 1373 51.2
Age
0-14 335 12.5
15-24 768 28.6
25-34 773 28.8
35-44 424 15.8
45-54 212 7.9
55-64 99 3.7
≥65 73 2.7
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HCV prevalence and incidence due to lack of proper
health facilities, poor economical status and less public
awareness about the transmission of major communicable
diseases [9].
Suppression of HBV replication by HCV in acutely or
chronically infected patients is well-described phenomenon.
In vivo study, in chimpanzees, showed that acute HCV
super infection in chronic HBV infection resulted in
marked reduction in the titer of serum HBsAg [10,11].
Both HBV and HCV share similar modes of transmis-
sion and co-infection with the two viruses is common,
especially in areas with a high prevalence of HBV infec-
tion and among people at high risk of parenteral infec-
tion [12]. Hepatitis B virus and hepatitis C virus can be
transmitted by transfusion of infected blood and carry-
ing out healthcare procedures using contaminated in-
struments and other unsafe practices. Perinatal and
sexual exposures to HBV are also highly efficient modes
of transmission [13]. Patients with dual HBV and HCV
infection have more severe liver disease, and are at in-
creased risk of progression to HCC [12]. Chronic infec-
tion develops in the majority of people infected with
HBV early in life while the majority of people infected
with HBV as adults will recover completely [3].
Generally, patients who are clinically suspected for HBV
and HCV have been consistently shown to have high preva-
lence of infection. Knowledge about the situation of hepa-
titis infection in developing countries like Ethiopia is
limited. Awareness about the seriousness of this condition
is limited among the care takers. Thus this study was
conducted to determine extent of hepatitis infection among
patients attending serology laboratory of Gondar University
Teaching Hospital.
Method
Study design and area
A retrospective study was conducted among clinically
suspected hepatitis patients attending serology laboratory
of Gondar University Teaching Hospital from January 2007
to December 2011. Gondar University Teaching Hospital is
situated in Gondar Town, located 747 km away from Addis
Ababa, capital city of Ethiopia. It acts as referral centre for
four district hospitals in the area. It has a range of special-
ties including pediatrics, surgery, gynecology, psychiatry,
HIV care and an outpatient’s clinic and serves a population
of more than five million across the region. As a teaching
hospital, it plays an important role in teaching, research
and community service.
The study populations were all patients who gave blood
and tested for HBV and HCV at Gondar University Teach-
ing Hospital from January 2007 to December 2011.
Data were collected from log book of serology laboratory
of Gondar University Teaching Hospital after checking thecompleteness of patients’ data. Data were entered and
analyzed by using SPSS version 16 statistical software. Dif-
ferences in proportions were evaluated by Pearson’s chi-
square and p<0.05 were considered to be statistically
significant.
Data were collected after ethical clearance obtained
from the School of Biomedical and Laboratory Sciences,
College of Medicine and Health Science, University of
Gondar. Permission was obtained from the Head of ser-
ology laboratory, Gondar University Teaching Hospital
before the data collection.
Result
A total of 2,684 serologically tested patients were included.
Of these, 1,373 (51.2%) were females and 1,311 (48.8%)
were males. The majority of study subjects 1,541 (57.4%)
were aged from 15–34 years old [Table 1]. The overall
prevalence of HBV and HCV was 14.6% and 12.41% re-
spectively. There was significant difference among gender
with p value of 0.011 for HBV (male=7.9%, female=6.3%)
and 0.001 for HCV (male =7.6%, female 4.13%). The major-
ity of infected individuals were aged 15–34 years old for
both HBV and HCV infection with p-value 0.36 and <0.001
respectively.
HBV was found to be more prevalent among study sub-
jects aged 25–34 years old (30.2%) and HCV was more
prevalent among those aged 15–24 years old (30.7%).
Among seropositve study subjects, 251 (18.28%) were fe-
males and 348 (6.25%) were males. The prevalence of co-
infection was comparatively high in males. Of HBV and
HCV mixed infected 36 (2%) study subjects, 1.3% were
males and 0.7% were females (p-value<0.001) [Table 2].
The majority of co-infected study subjects were 15–24
years old 27.8% (p-value<0.001). The prevalence of HBV
and HCV was relatively fluctuating from year to year. The
prevalence of HBsAg was 1.5% in 2007, 3.2% in 2008 and
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prevalence was 0.0% in 2007, 2.3% in 2008, 3.6% in 2009,
1.8% in 2010 and 0.9% in 2011 [Figure 1].40
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Figure 1 Trend prevalence of HBV, HCV and HBV-HCV co-
infection at serology laboratory of Gondar University Teaching
Hospital from January 2007 to December 2011.Discussion
HBV and HCV infections are serious health problems
which affect approximately two billion and one hundred
seventy million people across the world, respectively [7].
In this study the prevalence of HBV and HCV was 14.6%
and 12.4% respectively. However, similar study conducted
in Gondar, Mekele, Bahirdar and Addis Ababa among
blood donors showed lower prevalence of HBV and HCV
[14-16]. This inconsistency might be due to exclusion of
donors with clinical sign and symptom of hepatitis for
blood donation.
Moreover, a study conducted in Pakistan [17] showed
3.94% HBV infected males which is lower as compared to
the present study (7.9%). Another similar study conducted
in Pakistan surgical outpatient diseases indicated a preva-
lence of 8.6% HBsAg positve and 10.8% HCV positive
among males [18]. This finding is almost similar to the
present study. A study conducted in Egypt on intravenous
drug addicts revealed 24% cases of HBsAg positive and
33% was positive for anti-HCV. This study was inconsist-
ent with the present study which might be due to differ-
ences in study subjects who were highly vulnerable to
hepatitis infection due to shared use of needle and more
parenteral exposure [19].
Another study conducted in Sudan Maternity Hospital
reported that 5.6% was positive for HBsAg [20]. This study
was in line with the present finding (6.27%) on females. A
prospective study conducted in Addis Ababa, Ethiopia re-
vealed a total prevalence of 4.7% [21] HBV infected which
is inconsistent with the present study (14.6%). This mightTable 2 Percentage of HBV, HCV and HBV-HCV co-infection a
University teaching Hospital from January 2007 to December
Variables Total HBV
suspected (%)
HBsAg
positive (%)
α2 P-
value
Total HCV
suspected (%)
HCV
posi
Sex
Male 1275(49.1) 205(55.7) 9.07 0.011 924(49.6) 143(
Female 1324(50.9) 163(44.3) 938(50.4) 88(3
Age
0-14 322 37(10.1) 13.1 0.36 222 18(7
15-24 742 90(24.5) 489 71(3
25-34 750 111(30.2) 536 58(2
35-44 414 69(18.8) 311 40(1
45-54 205 39(10.6) 171 23(1
55-64 96 14(3.8) 77 18(7
≥65 70 8(2.2) 56 3(1.3be due to the difference in the study period, study design
and study subjects.
Furthermore, a prospective study conducted in Pakistan
showed 0.9% and 2.5% prevalence of HCV among females
and males respectively [17]. This result is inconsistent with
the present study which was 4.13% in females and 7.6% in
males. This inconsistency might be due to variation in
study population,-screening methods and study design.
Another study conducted in Nigeria revealed 8.3%
HBV-HCV co-infection [16]. This finding is inconsistent
with the current study which is 2%. A prospective study
conducted in Burkina Faso showed prevalence of 29.4%
HBsAg positive, 3.9% HCV positive and 2.2% HBV-HCV
co-infection. The prevalence of HBV-HCV co-infection
is in line with our study [22].
In this study we tried to provide insights of hepatitis
virus prevalence which is not well studied in the area.
Since the study is secondary data based finding; data in-
completeness and poor document retention system were
limitation of this study.mong study subjects at serology laboratory of Gondar
2011
tive (%)
α2 P-
value
Total HBV-HCV
suspected (%)
HBsAg and
HCV positive (%)
α2 P-
value
61.9) 17.4 <0.001 672(47.3) 23(63.9) 5.4 <0.00
8.1) 750(52.7) 13(36.1) 1
.8) 53.6 <0.001 177 4(11.1) 5.4 <0.00
0.7) 374 10(27.8) 1
5.1) 414 9(25.0)
7.3) 235 7(19.4)
0) 120 2(5.6)
.8) 56 4(11.1)
) 46 0 (0)
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The overall prevalence of HBV and HCV is higher in males
and age group of 15–34 years old. The trend prevalence is
still going constantly which may affect this productive age
group especially males. It is recommended if immunization
program among adults is implemented in the setup. Infor-
mation about the transmission, prevention and awareness
of viral hepatitis infection should be strengthened by giving
health education and herd immunization.
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